Peptides Similar to GDF-8

Compounds Related to GDF-8 (Myostatin)#

Myostatin sits at the center of a complex signaling network within the TGF-beta superfamily. Understanding related proteins and therapeutic compounds provides context for the ongoing development of muscle-targeting therapies.

GDF-11 -- The Close Relative#

GDF-11 (Growth Differentiation Factor 11) shares 90% amino acid sequence identity with myostatin in the mature domain and signals through the same receptors (ActRIIB and ALK4/5). Despite this structural similarity, GDF-11 has a broader tissue distribution and distinct biological roles. While early reports suggested GDF-11 might act as an "anti-aging" factor in the blood, subsequent research has produced conflicting results on this topic.

The high similarity between GDF-8 and GDF-11 creates a significant challenge for drug development: most myostatin-targeting antibodies and all ActRIIB-based inhibitors also block GDF-11 signaling. Whether co-inhibition of GDF-11 is beneficial or harmful in the context of muscle disease therapy remains an active area of investigation. Some researchers have suggested that selective myostatin inhibition, sparing GDF-11, might be preferable, while others argue that combined inhibition could be advantageous.

Follistatin -- The Natural Antagonist#

Follistatin is the best-characterized natural antagonist of myostatin. It binds directly to the mature myostatin dimer and prevents receptor engagement. Follistatin gene therapy using AAV1-FS344 has shown encouraging results in clinical trials for Becker muscular dystrophy and inclusion body myositis. However, follistatin also binds activins, GDF-11, and certain BMPs, making it a broad-spectrum TGF-beta superfamily inhibitor rather than a myostatin-specific agent.

Anti-Myostatin Antibodies#

Several monoclonal antibodies have been developed to specifically target myostatin:

• Stamulumab (MYO-029): First-in-class anti-myostatin antibody; Phase I/II completed; safe but limited efficacy
• Domagrozumab (PF-06252616): Anti-myostatin antibody; Phase 2 in DMD; did not meet primary endpoints
• Trevogrumab (REGN1033): Anti-myostatin antibody; tested in sarcopenia; modest lean mass gains

The antibody approach offers the theoretical advantage of myostatin specificity (not affecting activins or GDF-11), but clinical results have been disappointing, raising questions about whether myostatin-specific inhibition is sufficient for meaningful functional improvement.

Soluble Receptor Decoys#

ActRIIB-Fc fusion proteins act as ligand traps, binding myostatin and other ActRIIB ligands:

• ACE-031: Soluble ActRIIB-Fc; showed potent muscle growth effects but was discontinued due to off-target effects (epistaxis, telangiectasia from BMP9/10 inhibition)
• Bimagrumab (BYM338): Anti-ActRIIA antibody; showed increases in lean body mass but inconsistent functional improvements

Activin A#

Activin A is another TGF-beta superfamily ligand that signals through ActRIIB and acts as a negative regulator of muscle mass. Recent research suggests that combined inhibition of both myostatin and activin A may be more effective than targeting myostatin alone, as activin A can partially compensate for loss of myostatin signaling. This has led to renewed interest in broader-spectrum inhibitors.

Comparative Summary#

Related Reading#

• GDF-8 overview and research guide
• GDF-8 research evidence
• GDF-8 dosing protocols